Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!)

European Journal of Radiology

Volumn 69, Issue 2, 2009, Pages 204-208

  Mabille, Mylène ^a,b   Vanel, Daniel ^a,c   Albiter, Marcela ^d   Le Cesne, Axel ^a   Bonvalot, Sylvie ^a   Le Péchoux, Cécile ^a   Terrier, Philippe ^a   Shapeero, Lorraine G ^e,f   Dromain, Clarisse ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^f United States Military Cancer Institute   (United States)

Author keywords

GIST; Imatinib; Sarcomas of the soft tissue: translational oncology invasion and metastasis; Treatment evaluation; Tumor imaging: CT and MRI

Indexed keywords

GIST; IMATINIB; SARCOMAS OF THE SOFT TISSUE: TRANSLATIONAL ONCOLOGY-INVASION AND METASTASIS; TREATMENT EVALUATION; TUMOR IMAGING: CT AND MRI;

ABERRATIONS; AMINO ACIDS; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC RADIOGRAPHY; ELECTRIC INSTRUMENT TRANSFORMERS; FOURIER TRANSFORMS; MEDICAL IMAGING; ONCOLOGY; OPTICAL PROPERTIES; PATHOLOGY; TOMOGRAPHY;

TUMORS;

CONTRAST MEDIUM; IMATINIB; IOHEXOL; MEGLUMINE IOXITALAMATE PLUS SODIUM IOXITALAMATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PERITONEUM METASTASIS; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOCYST; RADIOLOGY; RECURRENT DISEASE; THICKNESS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PIPERAZINES; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 59649102913     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.10.009     Document Type: Article

References (12)

1. Sarlomo-Rikala M., Kovatich A.J., Barusevicius A., et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod. Pathol. 11 (1998) 728-734
2. De Mestier P., and Guetz G.D. Treatment of gastrointestinal stromal tumors with Imatinib Mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. World J. Surg. 29 (2005) 357-361
3. Verweij J., Judson I., and Van Oosterom A. STI571: a magic bullet?. Eur. J. Cancer 37 (2001) 1816-1819
4. Ray-Coquard J., Le Cesne A., and Blay J.Y. STI571 and gastrointestinal stromal tumors. Bull. Cancer 88 (2001) 661-662
5. WHO. Handbook for reporting results of cancer treatment 48 (1979), WHO Press, World Health Organisation Offset Publication, Geneva
6. Padhani A.R., and Ollivier L. The RECIST criteria: implications for diagnostic radiologists. Br. J. Radiol. 74 (2001) 983-986
7. Vanel D., Albiter M., Shapeero L.G., et al. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under Imatinib Mesylate treatment: a prospective study of 54 patients. Eur. J. Radiol. 54 (2005) 118-123
8. Chen T.W., Liu R.Y., Shyu R.Y., et al. Giant malignant gastrointestinal tumors: recurrences and effects of treatment with STI 571. World J. Gastroenterol. 11 (2005) 260-263
9. Goerres G.W., Stupp R., Barghouth G., et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumors: long-term outcome of treatment with Imatinib Mesylate. Eur. J. Nucl. Med. Mol. Imaging 32 (2004) 153-162
10. Choi H., Charnsangavej C., De Castro Faria S., et al. CT evaluation of the response of gastrointestinal stromal tumors after Imatinib Mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am. J. Roentgenol. 183 (2004) 1619-1628
11. Gelibter A., Milella M., Ceribelli A., et al. PET scanning evaluation of response to Imatinib Mesylate therapy in gastrointestinal stromal tumor (GIST) patients. Anticancer Res. 24 (2004) 3147-3151
12. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25 (2007) 1753-1759